Literature DB >> 18514320

The canine model with chronic, complete atrio-ventricular block.

Avram Oros1, Jet D M Beekman, Marc A Vos.   

Abstract

Proarrhythmic susceptibility to drug-induced Torsades de Pointes is restricted to individuals with a predisposed phenotype characterized by a reduced repolarization reserve. Additional factors are often involved in a further impairment of repolarization, possibly culminating with dangerous ventricular polymorphic tachyarrhythmias. Drugs that block repolarizing currents represent such an additional hit. The dog model with chronic, complete atrio-ventricular block has been used frequently for proarrhythmic drug screening. The ventricular remodeling seen after ablation of the AV node enhances the susceptibility for repolarization-dependent arrhythmias. In this review, we 1) describe the cellular and molecular basis of ventricular remodeling, 2) validate the CAVB dog as a drug screening model and 3) introduce a new surrogate predictive proarrhythmic parameter: beat-to-beat variability of repolarization.

Entities:  

Mesh:

Year:  2008        PMID: 18514320     DOI: 10.1016/j.pharmthera.2008.03.006

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  26 in total

Review 1.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  A Miniaturized, Programmable Pacemaker for Long-Term Studies in the Mouse.

Authors:  Maarten Hulsmans; Aaron D Aguirre; Matthew D Bonner; Aneesh Bapat; Sebastian Cremer; Yoshiko Iwamoto; Kevin R King; Filip K Swirski; David J Milan; Ralph Weissleder; Matthias Nahrendorf
Journal:  Circ Res       Date:  2018-11-09       Impact factor: 17.367

3.  Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.

Authors:  L Nalos; R Varkevisser; M K B Jonsson; M J C Houtman; J D Beekman; R van der Nagel; M B Thomsen; G Duker; P Sartipy; T P de Boer; M Peschar; M B Rook; T A B van Veen; M A G van der Heyden; M A Vos
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 4.  Cardiac electrical remodeling in health and disease.

Authors:  Michael J Cutler; Darwin Jeyaraj; David S Rosenbaum
Journal:  Trends Pharmacol Sci       Date:  2011-03       Impact factor: 14.819

Review 5.  Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk.

Authors:  András Varró; István Baczkó
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

6.  Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action.

Authors:  A Oros; M J Houtman; P Neco; A M Gomez; S Rajamani; P Oosterhoff; N J Attevelt; J D Beekman; M A G van der Heyden; L Ver Donck; L Belardinelli; S Richard; G Antoons; M A Vos
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 7.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

8.  The electromechanical window is no better than QT prolongation to assess risk of Torsade de Pointes in the complete atrioventricular block model in dogs.

Authors:  T R G Stams; V J A Bourgonje; H D M Beekman; M Schoenmakers; R van der Nagel; P Oosterhoff; J M van Opstal; M A Vos
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

9.  Perpetuation of torsade de pointes in heterogeneous hearts: competing foci or re-entry?

Authors:  Nele Vandersickel; Teun P de Boer; Marc A Vos; Alexander V Panfilov
Journal:  J Physiol       Date:  2016-03-04       Impact factor: 5.182

Review 10.  Animal models of arrhythmia: classic electrophysiology to genetically modified large animals.

Authors:  Sebastian Clauss; Christina Bleyer; Dominik Schüttler; Philipp Tomsits; Simone Renner; Nikolai Klymiuk; Reza Wakili; Steffen Massberg; Eckhard Wolf; Stefan Kääb
Journal:  Nat Rev Cardiol       Date:  2019-08       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.